Achondroplasia is the most common form of disproportionate short stature, also known as dwarfism, in humans. Vosoritide is the first medicine to be approved to treat children with achondroplasia. To help lay audiences understand the results from two clinical studies looking at vosoritide as a potential treatment for children with achondroplasia, a new plain language summary has just been published in Future Rare Diseases. The article, called ‘Vosoritide treatment accelerates bone growth in children with achondroplasia’ provides an easy-to-understand summary of the studies, written in straightforward language complemented with engaging visuals.
Read the Plain Language Summary in full here.
The original articles summarised in this plain language summary can be found below.
Study A is called ‘C-type natriuretic peptide analogue therapy in children with achondroplasia’ and was published in the New England Journal of Medicine. It can be read here.
Study B is called ‘Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, Phase 3, placebo-controlled, multicentre trial’ and was published in The Lancet. It can be read here.